A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors

Trial Profile

A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs AZD 1390 (Primary)
  • Indications Brain metastases; Glioblastoma
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Mar 2018 Planned initiation date changed from 28 Feb 2018 to 23 Mar 2018.
    • 09 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top